Department of Reproductive Medicine, Amsterdam UMC location Vrije Universiteit Amsterdam, De Boelelaan 1117, 1081 HV, Amsterdam, The Netherlands.
Amsterdam Reproduction and Development, Amsterdam, The Netherlands.
BMC Womens Health. 2022 Apr 18;22(1):123. doi: 10.1186/s12905-022-01707-z.
In women with unexplained infertility, tubal flushing with oil-based contrast during hysterosalpingography (HSG) increases ongoing pregnancy and subsequent live birth rates when compared to tubal flushing with water-based contrast. It is currently unclear whether an HSG with oil-based contrast also results in more ongoing pregnancies and live births in women of advanced age, women with ovulation disorders, and women with potential tubal pathology when compared to an HSG with water-based contrast.
We plan an international, multicentre, open-label, randomized controlled trial (RCT) studying three groups of infertile women who have an indication for tubal patency testing according to their treating physician and additionally; (1) are 39 years of age or older, (2) have an ovulation disorder or (3) have a high risk for tubal pathology based on their medical history. Women with an allergy for iodinated contrast medium are excluded, as are women with diabetes, hyperprolactinemia or untreated hyper- or hypothyroidism, and women with a partner with severe male infertility. After informed consent, women will be randomly allocated to the intervention, tubal flushing with the use of oil-based contrast during HSG or the control group, tubal flushing with the use of water-based contrast during HSG in a 1:1 ratio by the web-based system Castor. The primary endpoint will be ongoing pregnancy leading to live birth with conception within six months after randomization. Secondary outcomes are other pregnancy outcomes, used fertility treatments, adverse events and cost-effectiveness. Based on the expected ongoing pregnancy rate of 17% in the control group and 27% in the intervention group, the sample size will be 930 women (465 per group). Study inclusion is expected to be complete in four years.
This multicentre RCT will establish whether, for women of advanced age, women with ovulatory disease, and women who have a high risk for tubal pathology, there is a fertility enhancing effect of tubal flushing with oil-based contrast during HSG and whether the use of this contrast medium is cost-effective. Trial Registration The study was prospectively registered in the Netherlands Trial Register on August 1st 2019 as 'H2Oil2' (reference number NL7925, https://www.trialregister.nl/trial/7925 ).
在不明原因不孕的女性中,与水基造影剂相比,子宫输卵管造影(HSG)中使用油基造影剂进行输卵管冲洗可提高持续性妊娠和随后的活产率。目前尚不清楚与水基造影剂相比,油基造影剂的 HSG 是否也会导致高龄妇女、排卵障碍妇女和潜在输卵管疾病风险妇女的持续性妊娠和活产率更高。
我们计划进行一项国际性、多中心、开放标签、随机对照试验(RCT),研究三组有输卵管通畅性检测指征的不孕妇女,这些指征是根据其治疗医生确定的,另外:(1)年龄在 39 岁或以上,(2)排卵障碍,或(3)根据其病史有高风险的输卵管病变。对碘造影剂过敏的妇女、患有糖尿病、高催乳素血症或未经治疗的甲状腺功能亢进或甲状腺功能减退症的妇女以及患有严重男性不育症的伴侣的妇女被排除在外。在获得知情同意后,妇女将被随机分配到干预组,即 HSG 中使用油基造影剂进行输卵管冲洗,或对照组,即 HSG 中使用水基造影剂进行输卵管冲洗,两组比例为 1:1,通过网络系统 Castor 进行随机分配。主要终点是随机分组后 6 个月内导致活产的持续性妊娠。次要结局是其他妊娠结局、使用的生育治疗、不良事件和成本效益。基于对照组 17%和干预组 27%的预期持续性妊娠率,样本量为 930 名妇女(每组 465 名)。预计四年内完成研究纳入。
这项多中心 RCT 将确定对于高龄妇女、排卵障碍妇女和有高风险输卵管病变的妇女,HSG 中使用油基造影剂进行输卵管冲洗是否有提高生育能力的效果,以及使用这种造影剂是否具有成本效益。试验注册 该研究于 2019 年 8 月 1 日前瞻性地在荷兰试验注册中心注册为“ H2Oil2”(注册号 NL7925,https://www.trialregister.nl/trial/7925)。